On November 26, 2001 Amersham Health, the leader in medical diagnostic imaging, a major provider of radiotherapy products, and a business of Amersham plc, (LSE,NYSE,OSE:AHM), announced that it had received approval from the FDA for the expanded use of Myoview™ (Kit for the Preparation of Technetium Tc-99m Tetrofosmin for Injection) with pharmacologic stress agents in patients with known or suspected coronary artery disease, who are unable to physically exercise.

"The Pharmacological Stress indication is an important addition to the label claims for MYOVIEW in the U.S., and serves to reinforce the clinical versatility of this valuable product in the diagnosis of heart disease, which is one of the leading causes of death and disability," said Dr. John Padfield, Chief Executive Officer, Amersham Health. "We remain committed to expanding the clinical versatility of MYOVIEW on a global basis."

In studying patients with known or suspected coronary artery disease, care should be taken to ensure continuous cardiac monitoring and the availability of emergency cardiac treatment. As with all injectable drug products, allergic reactions, and anaphylaxis may occur.
 
Pharmacologic induction of cardiovascular stress may be associated with serious adverse events, such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction, and cerebrovascular events. Caution should be used when pharmacologic stress is selected as an alternative to exercise; it should be used when indicated and in accordance with the pharmacologic stress agent's labeling. The most common adverse reactions reported from post-marketing experience included rash, urticaria, abnormal vision, allergic reactions, and fever.